JP7644777B2 - ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程 - Google Patents

ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程 Download PDF

Info

Publication number
JP7644777B2
JP7644777B2 JP2022564209A JP2022564209A JP7644777B2 JP 7644777 B2 JP7644777 B2 JP 7644777B2 JP 2022564209 A JP2022564209 A JP 2022564209A JP 2022564209 A JP2022564209 A JP 2022564209A JP 7644777 B2 JP7644777 B2 JP 7644777B2
Authority
JP
Japan
Prior art keywords
heterodimeric
certain embodiments
fusion protein
antibody
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022564209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522972A (ja
JP2023522972A5 (cg-RX-API-DMAC7.html
Inventor
ビゲロウ，ミッチェル
ブラウン，アレクサンドラ
エフ チョン，アン
キュイユロ，ジャン－マリー
デローズ，マーク
グリンバーグ，アシャ
グティエレス，エバ
カービー，パトリック
ライアン モーガン，クリストファー
シー ネイル，マイケル
オニール，スティーブン
シフリン，マイケル
ヴァクトマン，ニコライ
Original Assignee
ドラゴンフライ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドラゴンフライ セラピューティクス， インコーポレイテッド filed Critical ドラゴンフライ セラピューティクス， インコーポレイテッド
Publication of JP2023522972A publication Critical patent/JP2023522972A/ja
Publication of JP2023522972A5 publication Critical patent/JP2023522972A5/ja
Priority to JP2024202517A priority Critical patent/JP2025037910A/ja
Application granted granted Critical
Publication of JP7644777B2 publication Critical patent/JP7644777B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022564209A 2020-04-22 2021-04-22 ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程 Active JP7644777B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024202517A JP2025037910A (ja) 2020-04-22 2024-11-20 ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063013834P 2020-04-22 2020-04-22
US63/013,834 2020-04-22
US202063033161P 2020-06-01 2020-06-01
US63/033,161 2020-06-01
PCT/US2021/028701 WO2021216916A1 (en) 2020-04-22 2021-04-22 Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024202517A Division JP2025037910A (ja) 2020-04-22 2024-11-20 ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程

Publications (3)

Publication Number Publication Date
JP2023522972A JP2023522972A (ja) 2023-06-01
JP2023522972A5 JP2023522972A5 (cg-RX-API-DMAC7.html) 2024-04-30
JP7644777B2 true JP7644777B2 (ja) 2025-03-12

Family

ID=75919398

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022564209A Active JP7644777B2 (ja) 2020-04-22 2021-04-22 ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程
JP2024202517A Pending JP2025037910A (ja) 2020-04-22 2024-11-20 ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024202517A Pending JP2025037910A (ja) 2020-04-22 2024-11-20 ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程

Country Status (10)

Country Link
US (1) US20230272041A1 (cg-RX-API-DMAC7.html)
EP (1) EP4138778A1 (cg-RX-API-DMAC7.html)
JP (2) JP7644777B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230004746A (cg-RX-API-DMAC7.html)
CN (1) CN116096353A (cg-RX-API-DMAC7.html)
AU (1) AU2021260960A1 (cg-RX-API-DMAC7.html)
CA (1) CA3175809A1 (cg-RX-API-DMAC7.html)
IL (1) IL297495A (cg-RX-API-DMAC7.html)
MX (1) MX2022013112A (cg-RX-API-DMAC7.html)
WO (1) WO2021216916A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
IL312221A (en) 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
CN115575467A (zh) * 2022-09-30 2023-01-06 华润生物医药有限公司 一种检测重组人GLP-1-Fc融合蛋白的方法
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins
CN122122176A (zh) * 2023-11-03 2026-05-29 拓济医药（苏州）有限责任公司 基于Fc区的异二聚体分子及其用途
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013539787A (ja) 2010-10-11 2013-10-28 アッヴィ・インコーポレイテッド タンパク質の精製方法
WO2018208448A1 (en) 2017-05-11 2018-11-15 Emd Millipore Corporation Method of maintaining narrow residence time distributions in continuous flow systems
WO2018237159A1 (en) 2017-06-21 2018-12-27 Cephalon, Inc. WASH PAD FOR CATIONIC EXCHANGE CHROMATOGRAPHY
JP2019536734A (ja) 2016-08-10 2019-12-19 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
JP2022505871A (ja) 2018-10-23 2022-01-14 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体ｆｃ融合タンパク質

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5391481A (en) 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
GB9022040D0 (en) 1990-10-10 1990-11-21 Biopharm Ltd Platelet adhesion inhibitor
US5851794A (en) 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0635029A4 (en) 1992-04-10 1996-01-24 Gen Hospital Corp MATRIX PROTEIN FROM CARTILAGE AND APPLICATION METHODS.
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6288214B1 (en) 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
AU1105700A (en) 1998-10-09 2000-05-01 Med Immune, Inc. Decorin binding proteins dbp a and b and genes encoding them
WO2000054731A2 (en) 1999-03-15 2000-09-21 The General Hospital Corporation Syndesmos and uses thereof
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6908994B1 (en) 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
AU5495500A (en) 1999-06-16 2001-01-02 The Texas A & M University System Decorin binding protein essential peptides and methods of use
AU5622800A (en) 1999-06-18 2001-01-09 Med Immune, Inc. Combined decorin binding protein and outer surface protein compositions and methods of use
IL150198A0 (en) 1999-12-15 2002-12-01 Res Dev Foundation Betaglycan as an inhibin receptor and uses thereof
US6777547B1 (en) 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
US6517838B1 (en) 2000-06-16 2003-02-11 The Texas A&M University System Decorin binding protein essential peptides and methods of use
WO2002024223A2 (en) 2000-09-21 2002-03-28 The Brigham And Women's Hospital, Inc. Prevention and treatment of streptococcal and staphylococcal infection
EP1411118B1 (en) 2001-06-22 2008-09-03 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican-3 antibody
US8192744B2 (en) 2002-08-26 2012-06-05 Ibcc Holding As Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
GB0406415D0 (en) 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
WO2005114186A1 (ja) 2004-05-20 2005-12-01 Wako Pure Chemical Industries, Ltd. ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法
JP2008502890A (ja) 2004-06-18 2008-01-31 エフ．ホフマン−ラ　ロシュ　アーゲー 結腸直腸癌のマーカーとしてのｃｂｐ２の使用
AU2005256113B2 (en) 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
WO2006023382A2 (en) 2004-08-23 2006-03-02 Albert Einstein College Of Medicine Of Yeshiva University Collagen vi and cancer
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
EP1896386B1 (en) 2005-06-08 2012-09-05 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1864996A1 (en) 2006-06-06 2007-12-12 Helmholtz-Zentrum für Infektionsforschung GmbH Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker.
HU0600578D0 (en) 2006-07-13 2006-09-28 Szilak Labor Bioinformatikai E Nuclear protein transport
EP2058659A4 (en) 2006-08-08 2009-10-21 Seikagaku Kogyo Co Ltd PROCESS FOR DETERMINING THE MOLECULAR WEIGHT OF HYALURONIC ACID
AU2008275985B2 (en) 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
CA2718707C (en) 2008-03-17 2018-01-02 University Of Miyazaki Method for detection of liver cancer cell using anti-glypican-3 antibody
US20090297479A1 (en) 2008-03-28 2009-12-03 Kiyoshi Ariizumi Dc-hil conjugates for treatment of t-cell disorders
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
ES2399584T3 (es) 2008-04-15 2013-04-02 Wako Pure Chemical Industries, Ltd. Nueva proteína capaz de unirse al ácido hialurónico y procedimiento para medir el ácido hialurónico usando la misma
JP2012503203A (ja) 2008-09-19 2012-02-02 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 基底乳癌腫の診断および処置のためのｃｓｐｇ４に対するモノクローナル抗体
GB0818273D0 (en) 2008-10-06 2008-11-12 Cambridge Entpr Ltd Modulation of cellular activity and differentiation
KR101105428B1 (ko) 2009-02-12 2012-01-17 경북대학교 산학협력단 글리피칸-3 단백질과 특이적으로 결합하는 펩타이드
WO2010129547A1 (en) 2009-05-04 2010-11-11 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for wound healing
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
CA2817779C (en) 2010-11-15 2019-02-19 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
US9206257B2 (en) 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US9217016B2 (en) 2011-05-24 2015-12-22 Symic Ip, Llc Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
EP2804586A4 (en) 2012-01-19 2016-03-16 Univ Johns Hopkins BIOMATERIALS CONTAINING HYALURONIC ACID BINDING PEPTIDES AND BIFUNCTIONAL BIOPOLYMERMOLUCKS FOR HYALURONIC ACIDIC TREATMENT AND TISSUE RENEWAL APPLICATIONS
WO2013163766A1 (en) 2012-05-04 2013-11-07 Cangene Corporation ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
CN104520331B (zh) 2012-06-01 2018-09-07 美国政府(由卫生和人类服务部的部长所代表) 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
US20160032007A1 (en) 2014-04-28 2016-02-04 Duke University Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4)
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
US10166304B2 (en) 2014-07-11 2019-01-01 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3218413A4 (en) 2014-11-12 2018-03-28 Memorial Sloan-Kettering Cancer Center Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
WO2016150884A1 (en) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
WO2016164429A1 (en) 2015-04-06 2016-10-13 The General Hospital Corporation Anti-cspg4 chimeric antigen receptors
AU2016276981B2 (en) * 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
US11370845B2 (en) 2015-06-24 2022-06-28 Keio University Anti-glypican-1-immunizing antigen receptor
EP3349770A1 (en) 2015-09-14 2018-07-25 Regents of the University of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
EP3353198B1 (en) 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3binding fibronectin based scafflold molecules
JP7461620B2 (ja) 2015-10-06 2024-04-04 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療用化合物及び方法
KR101796688B1 (ko) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
AU2017305170A1 (en) 2016-08-02 2019-02-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
MX2019004327A (es) * 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
US11248022B2 (en) 2017-03-08 2022-02-15 The Regents Of The University Of Michigan Glypican-3 peptide reagents and methods
CN110691793A (zh) 2017-04-26 2020-01-14 田边三菱制药株式会社 黏结蛋白聚糖-1（cd138）结合剂及其用
WO2018199318A1 (ja) 2017-04-28 2018-11-01 国立大学法人高知大学 抗ｇｐｃ－１抗体
RU2021110369A (ru) * 2017-09-07 2021-06-01 Драгонфлай Терапьютикс, Инк. Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
KR102884523B1 (ko) * 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013539787A (ja) 2010-10-11 2013-10-28 アッヴィ・インコーポレイテッド タンパク質の精製方法
JP2019536734A (ja) 2016-08-10 2019-12-19 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
WO2018208448A1 (en) 2017-05-11 2018-11-15 Emd Millipore Corporation Method of maintaining narrow residence time distributions in continuous flow systems
WO2018237159A1 (en) 2017-06-21 2018-12-27 Cephalon, Inc. WASH PAD FOR CATIONIC EXCHANGE CHROMATOGRAPHY
JP2022505871A (ja) 2018-10-23 2022-01-14 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体ｆｃ融合タンパク質

Also Published As

Publication number Publication date
AU2021260960A1 (en) 2022-11-24
IL297495A (en) 2022-12-01
JP2023522972A (ja) 2023-06-01
EP4138778A1 (en) 2023-03-01
CA3175809A1 (en) 2021-10-28
CN116096353A (zh) 2023-05-09
MX2022013112A (es) 2023-01-16
JP2025037910A (ja) 2025-03-18
KR20230004746A (ko) 2023-01-06
WO2021216916A1 (en) 2021-10-28
US20230272041A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
JP2025037910A (ja) ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程
US11787864B2 (en) Heterodimeric Fc-fused proteins
KR102776925B1 (ko) Flt3l-fc 융합 단백질 및 사용 방법
CN112638401B (zh) 抗肿瘤拮抗剂
CN109071656B (zh) 检查点调节物拮抗剂
TWI754622B (zh) Ctla4結合劑
JP6842926B2 (ja) Ｉｌ−１５ベース分子及びその使用方法
US20180147257A1 (en) Btn3a ectodomain proteins and methods of use
JP2025061790A (ja) がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン
CN112533944A (zh) 多特异性结合蛋白及其改进
JP2022514702A (ja) 二機能性抗ｐｄ－１／ｉｌ－７分子
JP2023517044A (ja) 融合タンパク質およびその使用
CA3122914A1 (en) Bifunctional anti-pd-1/sirp.alpha. molecule
US20220389394A1 (en) METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2023107956A1 (en) Proteins binding nkg2d, cd16 and 5t4
CN114340735A (zh) 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
CN113454116A (zh) Rank拮抗剂及其用途
WO2024133630A1 (en) Chemically disruptable molecule switch and use thereof
HK40071848B (en) Flt3l-fc fusion proteins and methods of use
EA045919B1 (ru) СЛИТЫЕ БЕЛКИ FLT3L-Fc И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK40011047A (en) Checkpoint regulator antagonists
EA046081B1 (ru) Мультиспецифические связывающие белки и их усовершенствования

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240417

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240417

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250228

R150 Certificate of patent or registration of utility model

Ref document number: 7644777

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150